FinanceAsianet Newsable
Sellas Life Sciences stock falls on China arbitration loss
in5points
Sellas Life Sciences (SLS) stock hit a one-month low after losing an arbitration case in China.
The company estimated $138.3 million in cash and cash equivalents as of June 30.
Retail investors called the drop a 'nothingburger' ahead of an AML (acute myeloid leukemia) readout.
The arbitration ruling is a setback for Sellas' operations in China.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically